Harris Ishtiyaq Shaafie, V R Koti, Kshitij Saxena, Priyanka Shukla
{"title":"结核菌素纯化蛋白衍生物和维生素D3对皮肤疣病灶内免疫治疗的随机对照研究。","authors":"Harris Ishtiyaq Shaafie, V R Koti, Kshitij Saxena, Priyanka Shukla","doi":"10.25259/jcas_178_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Numerous studies have been conducted on the clinical efficacy of immunotherapeutic agents in the treatment of cutaneous warts showing variable results. The present study aimed to compare the clinical efficacy and safety of intralesional tuberculin purified protein derivative (PPD) and Vitamin D<sub>3</sub> therapy in recurrent and recalcitrant extra-genital cutaneous warts.</p><p><strong>Material and methods: </strong>This study was conducted as a prospective, randomized, comparative, and single-blind study. A total of 104 patients were randomly distributed into two treatment groups: Group A (Tuberculin PPD, <i>n</i> = 53) and Group B (Vitamin D<sub>3</sub>, <i>n</i> = 51). Each patient in Group A received an intralesional injection of 0.1 mL tuberculin PPD (5 Tuberculin Units), while each patient in Group B received an intralesional injection of 0.2 mL Vitamin D<sub>3</sub> (Cholecalciferol containing 120,000 IU). The injections were given at the initial visit (week 0) and after every 2 weeks for a maximum of four sessions (weeks 2, 4, and 6). The largest wart was selected for intralesional therapy. The categorization of clinical response was done based on the percent reduction in the size of warts into complete (appearance of normal skin), marked (>50% reduction), moderate (<50% reduction), and inadequate (no change in warts) responses. Adverse effects (if any) were recorded during each patient visit. The final response was evaluated at 6 months follow-up from the last treatment session.</p><p><strong>Results: </strong>Regarding the response of patients to tuberculin PPD therapy, out of a total of 53 patients, 40 (75.5%) showed a complete response. Regarding the response of patients to Vitamin D<sub>3</sub> therapy, out of a total of 51 patients, 36 (70.6%) showed a complete response. However, the difference in the response to the treatment between the two groups was statistically insignificant (<i>P</i> = 0.402).</p><p><strong>Conclusion: </strong>Both intralesional tuberculin PPD and Vitamin D<sub>3</sub> are effective and safe in the treatment of all recurrent and recalcitrant extra-genital cutaneous warts.</p>","PeriodicalId":15415,"journal":{"name":"Journal of Cutaneous and Aesthetic Surgery","volume":"18 2","pages":"86-91"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980705/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intralesional immunotherapy of cutaneous warts using tuberculin purified protein derivative and vitamin D<sub>3</sub> - A randomized comparative study.\",\"authors\":\"Harris Ishtiyaq Shaafie, V R Koti, Kshitij Saxena, Priyanka Shukla\",\"doi\":\"10.25259/jcas_178_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Numerous studies have been conducted on the clinical efficacy of immunotherapeutic agents in the treatment of cutaneous warts showing variable results. The present study aimed to compare the clinical efficacy and safety of intralesional tuberculin purified protein derivative (PPD) and Vitamin D<sub>3</sub> therapy in recurrent and recalcitrant extra-genital cutaneous warts.</p><p><strong>Material and methods: </strong>This study was conducted as a prospective, randomized, comparative, and single-blind study. A total of 104 patients were randomly distributed into two treatment groups: Group A (Tuberculin PPD, <i>n</i> = 53) and Group B (Vitamin D<sub>3</sub>, <i>n</i> = 51). Each patient in Group A received an intralesional injection of 0.1 mL tuberculin PPD (5 Tuberculin Units), while each patient in Group B received an intralesional injection of 0.2 mL Vitamin D<sub>3</sub> (Cholecalciferol containing 120,000 IU). The injections were given at the initial visit (week 0) and after every 2 weeks for a maximum of four sessions (weeks 2, 4, and 6). The largest wart was selected for intralesional therapy. The categorization of clinical response was done based on the percent reduction in the size of warts into complete (appearance of normal skin), marked (>50% reduction), moderate (<50% reduction), and inadequate (no change in warts) responses. Adverse effects (if any) were recorded during each patient visit. The final response was evaluated at 6 months follow-up from the last treatment session.</p><p><strong>Results: </strong>Regarding the response of patients to tuberculin PPD therapy, out of a total of 53 patients, 40 (75.5%) showed a complete response. Regarding the response of patients to Vitamin D<sub>3</sub> therapy, out of a total of 51 patients, 36 (70.6%) showed a complete response. However, the difference in the response to the treatment between the two groups was statistically insignificant (<i>P</i> = 0.402).</p><p><strong>Conclusion: </strong>Both intralesional tuberculin PPD and Vitamin D<sub>3</sub> are effective and safe in the treatment of all recurrent and recalcitrant extra-genital cutaneous warts.</p>\",\"PeriodicalId\":15415,\"journal\":{\"name\":\"Journal of Cutaneous and Aesthetic Surgery\",\"volume\":\"18 2\",\"pages\":\"86-91\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980705/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous and Aesthetic Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25259/jcas_178_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous and Aesthetic Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/jcas_178_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的：对免疫治疗剂治疗皮肤疣的临床疗效进行了大量研究，结果不一。本研究旨在比较瘤内结核菌素纯化蛋白衍生物（PPD）和维生素D3治疗复发性和顽固性生殖器外皮肤疣的临床疗效和安全性。材料和方法：本研究采用前瞻性、随机、比较、单盲研究。104例患者随机分为两组：A组（结核菌素PPD， n = 53）和B组（维生素D3， n = 51）。A组患者病灶内注射结核菌素PPD 0.1 mL（5结核菌素单位），B组患者病灶内注射维生素D3 0.2 mL（含胆骨化醇120000 IU）。在首次就诊时（第0周）和每2周后注射一次，最多4次（第2、4和6周）。选择最大的疣进行局部治疗。临床反应的分类是根据疣大小减少的百分比分为完全（皮肤外观正常），显著（减少50%），中度(结果：关于患者对结核菌素PPD治疗的反应，总共53例患者中，40例（75.5%）显示完全缓解。关于患者对维生素D3治疗的反应，在51例患者中，36例（70.6%）显示完全缓解。但两组患者对治疗的反应差异无统计学意义（P = 0.402）。结论：瘤内结核菌素PPD和维生素D3治疗复发性难治性生殖器外皮肤疣有效、安全。
Intralesional immunotherapy of cutaneous warts using tuberculin purified protein derivative and vitamin D3 - A randomized comparative study.
Objectives: Numerous studies have been conducted on the clinical efficacy of immunotherapeutic agents in the treatment of cutaneous warts showing variable results. The present study aimed to compare the clinical efficacy and safety of intralesional tuberculin purified protein derivative (PPD) and Vitamin D3 therapy in recurrent and recalcitrant extra-genital cutaneous warts.
Material and methods: This study was conducted as a prospective, randomized, comparative, and single-blind study. A total of 104 patients were randomly distributed into two treatment groups: Group A (Tuberculin PPD, n = 53) and Group B (Vitamin D3, n = 51). Each patient in Group A received an intralesional injection of 0.1 mL tuberculin PPD (5 Tuberculin Units), while each patient in Group B received an intralesional injection of 0.2 mL Vitamin D3 (Cholecalciferol containing 120,000 IU). The injections were given at the initial visit (week 0) and after every 2 weeks for a maximum of four sessions (weeks 2, 4, and 6). The largest wart was selected for intralesional therapy. The categorization of clinical response was done based on the percent reduction in the size of warts into complete (appearance of normal skin), marked (>50% reduction), moderate (<50% reduction), and inadequate (no change in warts) responses. Adverse effects (if any) were recorded during each patient visit. The final response was evaluated at 6 months follow-up from the last treatment session.
Results: Regarding the response of patients to tuberculin PPD therapy, out of a total of 53 patients, 40 (75.5%) showed a complete response. Regarding the response of patients to Vitamin D3 therapy, out of a total of 51 patients, 36 (70.6%) showed a complete response. However, the difference in the response to the treatment between the two groups was statistically insignificant (P = 0.402).
Conclusion: Both intralesional tuberculin PPD and Vitamin D3 are effective and safe in the treatment of all recurrent and recalcitrant extra-genital cutaneous warts.
期刊介绍：
The journal will cover aspects of Dermatosurgery and Aesthetic surgery, including cutaneous surgical procedures, lasers, light based treatments and aesthetic treatments. Authors of articles addressing topics such as skin tumours, pigmentary disorders, histopathology, diagnostic techniques, drugs, applications of cosmeceuticals surgical aspects, including pre and post procedural care are highly encouraged to submit with us. The journal also publishes articles on topics in allied specialities suh as plastic surgery, maxillofacial surgery vascular surgery, oculoplastic surgery etc. that are relevant to Dermatosurgery. The journal gives preference to clinically oriented studies over experimental and animal studies. The Journal would publish peer-reviewed Original Research Articles, Systematic reviews, Narrative Reviews, Case reports, Innovations and Debates. Letters to the editor, practice points, pearls in cutaneous and aesthetic surgery, quiz page, images, novel techniques, newer uses of instruments and video presentations and ethical aspects of cutaneous and aesthetic surgery are also invited.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
